ASYMCHEM's stock soared 5.43% intraday on Monday, reflecting strong investor sentiment.
The surge follows the establishment of Asymchem's chemical macromolecule CDMO project in the Tianjin Economic-Technological Development Area. This initiative enhances the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better addressing the diverse needs of global partners.
Zheshang Securities noted that Asymchem's small-molecule CDMO business remains on a strong growth trajectory, with emerging segments like peptide and oligonucleotide-related CDMO, ADC-related CDMO, and formulation CDMO possessing substantial growth potential and earnings flexibility.
Comments